Glucotrack Announces 3 New Patents to Monitor Blood Glucose

50 second read

By Karen Roman

GlucoTrack, Inc. (Nasdaq: GCTK) said the U.S. Patent and Trademark Office issued three patents for its continuous blood glucose monitoring platform as the company moves toward commercializing it.

The three patents protect key technologies related to proprietary sensor chemistry, intravascular lead design, and low-power electronics, the company stated.

“Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization,” said Paul V. Goode, PhD, Glucotrack’s President and CEO. “These patents establish important competitive barriers and strengthen our position to deliver a differentiated approach to diabetes management.”